Subsequent Events	9 Months Ended
Jun. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	NOTE 15. Subsequent Events The Company has made a review of material subsequent events from June 30, 2022 through the date of issuance of this report. There are no subsequent events to report as of the issuance of these financial statements. We have completed, the clinical protocol for a new Investigational New Drug (IND) application that was filed on July 7, 2022 and were approved to proceed with the study on August 5, 2022 by the US Food and Drug Administration. Our efforts led to the development of a new study filed with the US FDA as a “first in human” study of ATCell in Long Covid titled: “A Pilot Study on Research Treatment OF Long Covid Post-Acute Sequelae of SARS CoV-2 Infection (“PASC”) Using ATCell™” the approved study is scheduled to be conducted at the Walter Reed National Military Medical Center (WRNMMC) in Bethesda, Maryland.

Subsequent Events

9 Months Ended

Jun. 30, 2022

NOTE 15. Subsequent Events

The Company has made a review of material subsequent events from June 30, 2022 through the date of issuance of this report. There are no subsequent events to report as of the issuance of these financial statements.

We have completed, the clinical protocol for a new Investigational New Drug (IND) application that was filed on July 7, 2022 and were approved to proceed with the study on August 5, 2022 by the US Food and Drug Administration. Our efforts led to the development of a new study filed with the US FDA as a “first in human” study of ATCell in Long Covid titled: “A Pilot Study on Research Treatment OF Long Covid Post-Acute Sequelae of SARS CoV-2 Infection (“PASC”) Using ATCell™” the approved study is scheduled to be conducted at the Walter Reed National Military Medical Center (WRNMMC) in Bethesda, Maryland.

AMERICAN CRYOSTEM Corp 10-Q